Archive for Recent

Recent US Hantavirus Cases Prompt New “How to Get Rid of Mice” Infographic

(PRWEB) April 28, 2015

Two cases of hantavirus in April 2015 have helped refocus attention on the dangers of living and working amongst rodent infestations. A 36-year old Colorado man has died (this being the second Colorado, hantavirus fatality already this year) while a 20-year old University of Montana student was seriously ill but is recovering.

Unlike rabies or many other animal-transmitted diseases where peculiar behavior may be a warning sign, carrier rodents appear to be unaffected by hantavirus. For infected humans, however, the death rate stands at 38%. There is currently no cure or vaccine but early treatment improves one’s odds of survival.

Spring Season Puts Us at Heightened Risk for Contracting This Deadly, Respiratory Disease.

Spring is an especially dangerous time for hantavirus exposure. It’s when we’re busy cleaning out cabins, sheds and enclosed areas that have been sealed up for the winter, and stirring up accumulated dust that’s contaminated with rodent saliva, urine and feces. Even working with rodent-contaminated garden soil has been cited as a possible source for infection with hantavirus. Breathing contaminated dust is the most common way that people become infected, though touching your nose or mouth with contaminated hands may also cause infection.

Thus far, hantavirus cases have been confirmed in 34 states, with the great majority being west of the Mississippi River. (In addition to hantavirus, however, rodents in the US can transmit 9 other directly-transmitted diseases and more than a dozen indirectly-transmitted diseases via the ticks, fleas and mites they carry.)

What Are the Symptoms of Hantavirus?

Early symptoms of hantavirus can appear anywhere between 1-6 weeks after exposure and mimic those of influenza: fever, fatigue, muscle ache, headache and/or chills. Within 4-10 days of the first symptoms, however, dry cough and difficulty breathing become pronounced, with possible cardiac and respiratory failure following shortly thereafter.

What Can You Do to Protect Yourself?

Steps should be taken to eradicate exiting rodent populations (especially mice, in the case of hantavirus) and prevent future infestations: exterior entryways (as small as 1/4″) should be closed off, existing populations trapped, etc. before cleanup efforts begin. To assist with this effort, has designed an online infographic that’s packed with information on how to rid your home of mice… and keep them out. It may be viewed and shared at

Open windows and doors for at least 30 minutes to help ventilate mice-contaminated areas before cleaning.

During cleanup, wear rubber, latex or vinyl gloves if signs of rodent activity are present. Ironically, dust masks and surgical masks do not provide protection against viruses(1) so it is important that dust be well saturated with bleach/water solution to prevent it from becoming airborne.

Any contaminated objects that can easily be moved (such as storage boxes), should be taken outside for cleaning. Hantavirus remains infectious for up to 2-3 days in the environment but can be inactivated more quickly with exposure to sunlight. Just be certain to stay upwind of dust that may become wind-blown.

Accumulated dirt and dust should be sprayed heavily with a 1:9 bleach/water solution. Rodent droppings and any dead rodents and nests should be soaked with this solution for 5 minutes before moving.

The same 1:9 bleach/water solution should be used to mop floors and disinfect countertops, cabinets, drawers, etc. Be careful to avoid stirring up dust into the air.

Clean with paper towels that can be discarded in a plastic trash bag, along with all debris, dead rodents, nest materials, etc. Seal bag tightly when full.

Place full trash bag into a second trash bag, seal tightly and place in a covered trash can for disposal.

Discard gloves and clean-up well with soap and warm water.

If you experience flu-like symptoms or difficulty breathing and have reason to believe that you may have been exposed to rodents, seek medical attention immediately.

To help rid your home of mice, has created an infographic entitled, “How to Get Mice to Move Out and Stay Out” that is posted online at We encourage you to become familiar with these tips and share them with others.


A commercial website that is dedicated to producing timely and important health and wellness information. Recent topics discussed at deal with diet and nutrition, weight management, heart disease and more.


Email: news(at)AlabamaHealth(dot)com

Sources (accessed 4/232/2015):

SHAPE Task Force Applauds Recent Urgent Calls to Overhaul CVD Prevention Guidelines

Houston, TX (PRWEB) November 12, 2014

Leading preventive cardiologists and academic cardiovascular specialists from the Society for Heart Attack Prevention and Eradication (SHAPE), a non-profit organization advocating for early detection of future heart attack victims, endorse and applaud Dr. Steven Nissen’s urgent call to improve upon the existing inaccurate guidelines for detection and prevention of cardiovascular disease.

“We are delighted to hear Dr. Nissen and other well established physicians in the cardiology community call for revising existing guidelines” said Dr. PK. Shah, Chairman of SHAPE Scientific Advisory Board. “As many of you know, we have raised flags repeatedly since 2005 when we announced the SHAPE Guidelines and are looking forward to the much needed overhaul”.

After 10 years, as the field of cardiology anxiously awaited the NCEP IV Guidelines, the SHAPE Task Force was disappointed that several clinically important discoveries of the past decade were not incorporated in the AHA-ACC “Pooled Cohort” Guidelines. The Guidelines did not assign a proper role to the detection of subclinical atherosclerosis.

“In the past decade, a mountain of evidence has amassed supporting the superiority of screening for atherosclerosis over screening for risk factors of atherosclerosis, specially for detecting those with the highest near-term risk “the Vulnerable Patient”, however, most physicians are still treating their patients based on the outdated NCEP Guidelines” said Dr. Morteza Naghavi, Founder of SHAPE and Executive Chairman of the SHAPE Task Force. “It is disappointing that while other countries started incorporating atherosclerosis testing in their diagnostic algorithms, the US, where the research was largely done, lags in this regard. It is time for the US physicians to adopt practicing detection and treatment of atherosclerosis.”

The large, consistent body of evidence has demonstrated the value of using noninvasive imaging for early detection of atherosclerosis in its pre-symptomatic stage as recommended by the SHAPE Guidelines. While assessment of traditional risk factors such as high cholesterol and high blood pressure are important, it is now clear that the direct measurement of atherosclerosis, which measures the lifetime effects of known and unknown risk factors, is essential in identifying high risk individuals and improves the accuracy of their risk classification. SHAPE Guidelines focus on early detection of atherosclerosis whereas the existing guidelines focus on epidemiological risk factors of atherosclerosis which depict the statistical probability of developing atherosclerosis. The burden of atherosclerotic plaques predicts adverse events much more accurately than risk factors of atherosclerosis, particularly near-term events.

“We need to adopt Personalized Medicine to advance our patient care” said Dr. Daniel Berman, Chief of Nuclear Cardiology at Cedars Sinai Medical Center in Los Angeles and a leading member of SHAPE Task Force. “Treating patients for atherosclerosis without knowing if they have atherosclerosis, is a blind approach. The SHAPE Guidelines is a major step toward Personalized Medicine for prevention of atherosclerotic cardiovascular disease”

In 2009, the Appropriate Use Criteria considered coronary artery calcium scoring (CAC) “appropriate” for asymptomatic adults with an “Intermediate” global risk estimate, as well as those deemed lower risk with a family history of premature coronary heart disease. In 2010, the ACC/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults followed suit, elevating CAC and carotid plaque and intima-media thickness (CIMT) to Class IIa recommendations for cardiovascular risk assessment in asymptomatic adults at intermediate (10% to 20% 10-year) risk.

“The ACC’s Appropriate Use Criteria and 2010 Guidelines for Assessing Cardiovascular Risk was a big step forward. Unfortunately the new 2013 AHA/ACC Guidelines reversed some progress leading to significant over-treatment, especially in female populations” said Mathew Budoff, Professor of Medicine at UCLA and a leading member of SHAPE Task Force. “Today, there is absolutely no doubt that coronary calcium imaging predicts cardiovascular events better than all risk markers put together, including Framingham Risk Score, hs-CRP, and other new biomarkers”

The new AHA-ACC “Pooled” Guideline1, with its arbitrary change in the definition of High Risk in the primary prevention setting, is likely to result in marked overtreatment and undue “High Risk” labeling and statin therapy of many healthy women. For example, a 65year old non-smoking, non-diabetic, non-hypertensive woman with total cholesterol of 200 mg/dl and HDL of 49 mg/dl who lives an active life style would now be recommended statin therapy. In contrast, the same individual would be defined as Low Risk by the 2010 ACCF/AHA2 and NCEP Guidelines. More importantly, regardless of her cholesterol levels, if this female is tested negative for atherosclerosis, (absence of coronary calcium, absence of carotid plaques, or normal carotid wall thickness), she will be truly a low-risk individual and would not need statin therapy. The use of the new Guidelines also results in overestimation of the need for medications in certain subgroups of men. On the other side of the spectrum, high-risk individuals, men and women, with normal or borderline risk factors but a significant level of atherosclerotic plaques are overlooked as they would not qualify for intensive therapy. The existing AHA-ACC Guidelines address the PROBABILITY of coronary atherosclerotic disease and do not take into account whether such an individual has any evidence of subclinical atherosclerosis.

The Guidelines should no longer blindly favor intensive cholesterol lowering independent of atherosclerosis, but instead must target intensive therapy for those individuals with the highest burden of atherosclerotic “the Vulnerable Patient” who are expected to benefit the most from aggressive cholesterol-lowering and other interventions. The heightened awareness of possible statin induced hyperglycemia (diabetes mellitus) reinforces the need for more accurate and individualized risk assessment to insure that widespread drug therapy is appropriately implemented.

SHAPE is continuing its scientific quest for innovative approaches to heart attack prevention, and ultimately, eradication. As an educational nonprofit organization, SHAPE advocates only the most scientifically proven approach, independent of specific practices or procedures. SHAPE is actively supporting the Department of Health & Human Services Million Hearts™ initiative to prevent one million heart attacks and strokes over 5 years and encourages the DHHS authorities to consider national adoption of SHAPE Guidelines which is much more like to identify and save “the Vulnerable Patient” at risk of adverse events over 5 years.

In conclusion, given the large, consistent and growing body of evidence showing that testing for subclinical atherosclerosis is a more accurate method of predicting atherosclerotic cardiovascular events than testing for risk factors of atherosclerosis, the SHAPE Task Force applauds recent calls for revision of existing guidelines and respectfully urges the authorities at the American Heart Association and American College of Cardiology and effectively incorporate screening for atherosclerosis in determining risk and correspond the intensity of therapy to the burden of atherosclerosis.



SHAPE encourages people to watch “Widowmaker”

About the Society for Heart Attack Prevention and Eradication (SHAPE):

Originated from Houston, Texas and founded by Dr. Morteza Naghavi, SHAPE is a non-profit organization and is supported by leading cardiologists and cardiovascular researchers worldwide. The mission of SHAPE is to eradicate heart attack by championing new strategies for prevention while promoting the scientific quest for a cure such as “vaccine for atherosclerosis”. The immediate focus of SHAPE is on proper risk assessment of the asymptomatic individuals who are at risk of sudden cardiovascular events. SHAPE is committed to raising public awareness about revolutionary discoveries that are opening exciting avenues to prevent and ultimately eradicate heart attacks. Through educational programs presented to both medical professionals and the community, SHAPE raises awareness for the primary prevention of atherosclerotic cardiovascular disease. The vision of SHAPE is a world free from heart attack in the 21st century. Additional information is available on the organization’s website at

About the SHAPE Task Force:

Morteza Naghavi, M.D. – Executive Chairman

PK Shah, M.D. – Chair of Scientific Board

Erling Falk, M.D., Ph.D. – Chief of Editorial Committee


Arthur Agatston, M.D., Michael Blaha, M.D.,M.P.H., Daniel S. Berman, M.D., Matthew J. Budoff, M.D., Michael H. Davidson, M.D., Jim Ehrlich, M.D., Raimund Erbel, M.D., Erling Falk, M.D., Ph.D., Steven B. Feinstein, M.D., Craig Hartley, Ph.D., Harvey S. Hecht, M.D., Howard Hodis, M.D., Ioannis Kakadiaris, Ph.D., Sanjay Kaul, M.D., M.P.H., Iftikhar J. Kullo, M.D., Daniel Lane, M.D., Ph.D., Marge Lovell, R.N., Ralph Metcalfe, Ph.D., Morteza Naghavi, M.D., Tasneem Z. Naqvi, M.D., Khurram Nasir, M.D., Paolo Raggi, M.D., George P. Rodgers, M.D., John Rumberger, M.D., Ph.D., PK Shah, M.D., Leslee Shaw, Ph.D., David Spence, M.D., H. Robert Superko, M.D., Henrik Sillesen, M.D., Ph.D., Pierre-Jean Touboul, M.D.

Affiliation of Members of the SHAPE Task Force:

Arthur Agatston, M.D.

Associate Professor of Medicine,

University of Miami Miller School of Medicine

Founder and Director of the South Beach Diet and Heart Health Program

Miami, FL

Michael Blaha, M.D. M.P.H.

The Johns Hopkins

Ciccarone Center for the Prevention of Heart Disease

Baltimore, MD

Daniel S. Berman, M.D.

Director of Cardiac Imaging and of Nuclear

Cardiology at Cedars-Sinai

Los Angeles, CA

Matthew Budoff, M.D.

Vice President, Society of Atherosclerosis Imaging,

Professor of Medicine and Director of Preventive

Cardiology, UCLA Harbor

Los Angeles, CA

Michael H. Davidson, M.D.

FNLA Professor, Director of Preventive Cardiology, The University of Chicago Pritzker School of Medicine, Executive Medical Director,

Radiant Research

Chicago, IL

James Ehrlich, M.D.

Clinical Associate Professor

University of Colorado

Denver, CO

Raimund Erbel, M.D.

Professor of Medicine

University of Duisburg-Essen

Director of Department of Cardiology

West German Heart Center

Essen, Germany

Erling Falk, M.D., Ph.D.

Chief of SHAPE Guidelines Editorial Committee

Professor of Pathology and Cardiology

Aarhus University Hospital (Skejby)

Aarhus, Denmark

Steven B. Feinstein, M.D.

Professor of Medicine and Director of Echocardiograpy

Division of Cardiology, Rush University Medical Center

Chicago, IL

Craig Hartley, Ph.D.

Professor of Bioengineering

Baylor College of Medicine

Houston, TX

Harvey S. Hecht, M.D.

Professor of Medicine

Associate Director of Cardiac Imaging

The Mount Sinai Medical Center

New York, NY

Howard Hodis, M.D.

Professor of Cardiology and Preventive Medicine

Professor for Molecular Pharmacology and Toxicology

Director of Atherosclerosis Research Unit at the Division of Cardiovascular Medicine

Keck School of Medicine University of Southern California

Los Angeles, CA

Ioannis Kakadiaris, Ph.D.

Professor of Biomedical Computer Sciences

University of Houston<

Houston, TX

Sanjay Kaul, M.D., M.P.H.

Director, Cardiology Fellowship Training Program

Director, Vascular Physiology and Thrombosis Research

Laboratory at the Burns and Allen Research Institute

Cedars-Sinai Medical Center

Los Angeles, CA

Iftikhar J. Kullo, M.D.

Professor of Medicine

Division of Cardiovascular Disease

College of Medicine

Mayo Clinic

Rochester, MN

Roxana Mehran, M.D.

Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials, Mount Sinai Heart, the Zena and Michael A. Wiener Cardiovascular Institute

Mount Sinai School of Medicine

New York, NY

Ralph Metcalfe, Ph.D.,

Professor of Biomedical Engineering

University of Houston

Houston, TX

Morteza Naghavi, M.D.

Executive Chairman of SHAPE Task Force

President and CEO of MEDITEX

Houston, TX

Tasneem Z Naqvi, M.D. MMM

Professor of Medicine

Mayo College of Medicine

Director Echocardiography

Mayo Clinic


Khurram Nasir, M.D.


Center for Prevention and Wellness Research,

Baptist Health South Florida,

Miami, Florida

Paolo Raggi, M.D.

Academic Director, Mazankowski Alberta Heart Institute

University of Alberta

Edmonton, AB


George P. Rodgers, M.D.

Preventive Cardiology and Wellness Center

Seton Heart Institute

Austin, TX

John Rumberger, M.D.

Director of Cardiac Imaging

The Princeton Longevity Center,

Princeton, NJ

PK Shah, M.D.

Chairman of SHAPE Scientific Committee

Chief of Cardiology and Director of Atherosclerosis Research, Cedars Sinai Medical Center

Professor of Medicine at UCLA School of Medicine

Los Angeles, CA

Leslee Shaw, Ph.D.

Professor of Cardiology

Outcome Research Center

Emory University

Atlanta, GA

Henrik Sillesen, M.D., D.MSc.

Director of HRP Study Carotid Examinations

Chairman, Department of Vascular Surgery Rigshospitalet

Professor of Surgery, University of Copenhagen

Copenhagen, Denmark

J. David Spence, M.D.

Professor of Neurology and Clinical Pharmacology,

University of Western Ontario

Director of Stroke Prevention & Atherosclerosis Research Centre,

Robarts Research Institute

London, ON


H. Robert Superko, M.D.

President – Cholesterol, Genetics, and Heart Disease Institute

Adjunct Professor

Mercer University School of Pharmaceutical Sciences

Atlanta, GA

Pierre-Jean Touboul, M.D.

Professor of Neurology

Department of Neurology and Stroke Center

AP-HP Bichat University Hospital

Neurology and Stroke Center

Paris, France

ACTIVATE’s Unique Approach to ADHD Therapy Corroborated by Recent Studies

New Haven, Connecticut (PRWEB) November 04, 2014

A new study from Michigan State University concludes that 30 minutes of exercise each morning can dramatically improve ADHD symptoms in children. The study corroborates the physical exercise portion of C8 Sciences’ ACTIVATE™ program and provides invaluable clues as to the proper path forward in ADHD therapy.

C8 Sciences and independent ADHD therapy researchers have long suspected a link between physical exercise and cognitive health. The MSU study confirms that symptoms such as inattentiveness, mood swings, and poor social skills can be improved with just 30 minutes of physical activity each morning before school. The study took place over a 12-week period and examined 200 elementary-school students, some of whom showed signs of ADHD and some of whom did not.

The findings were decisive. All participants in the physical exercise program showed improvement, but the benefits were especially marked in those with symptoms of ADHD. Researchers were quick to point out that more studies would be needed for further clarification, but the early evidence points to an important link between exercise and beneficial impact.

Cognitive training programs like ACTIVATE™ incorporate physical exercise as part of a balanced, thorough approach to ADHD therapy. ACTIVATE™’s physical activity program was designed by Dr. Jinxia Dong, whose expertise comes both from her years as a Chinese national gymnast and her research work at Peking University. The programs are designed to increase neuroplasticity and improve cognitive skills using a different set of tools from the computer-based ACTIVATE™ software.

In both anecdotal evidence from users of ACTIVATE™ and independent ADHD studies, the results have been overwhelming. Recent research from the University of Illinois demonstrated a causal relationship between physical activity and improved executive control. The development of executive function in children with ADHD often lags behind their peers, contributing to a lack of self-control, increased distractibility, and poorer cognitive flexibility.

Programs such as ACTIVATE™ hone in on physical activity as an important part of reducing ADHD symptoms in children. Though computer-based training, medication, and social therapies can all do wonders when it comes to improving neuroplasticity, exercise is a crucial step in the process. Not only does it benefit a child’s overall health, it can be of exceptional benefit in taming distraction.

ACTIVATE™’s physical activity program remains the standard by which similar programs are judged. Developed with guidance from physical education teachers and experts, the program focuses on a variety of exciting and challenging skills that start simple before growing more complex. Over 100 different activities and exercises are included, all of which aim to improve social intelligence, emphasize cooperation, and reduce ADHD symptoms in children.

At a time when more than 10 percent of American children are diagnosed with ADHD and schools nationwide are underemphasizing physical education, programs like ACTIVATE™ are more important than ever. ACTIVATE™ is not intended as a substitute for proper medication, but rather as an adjunctive therapy that can enhance an ADHD student’s ability to learn, thrive, and function. As more evidence comes to light, researchers at C8 Sciences vow to incorporate the latest findings into their approach to ADHD therapy.